There are now over 200 prospective reports in the APR of first tr

There are now over 200 prospective reports in the APR of first trimester exposure for ABC, ATV, EFV, FTC, 3TC, LPV, NVP, ritonavir, TDF and ZDV. No signal of increased risk of congenital abnormality has been demonstrated, and a greater than twofold higher rate than in the general population has been excluded. There are, so far, fewer than 200 prospective reports for DRV, RAL and RPV within the APR and hence no reports on these agents are yet available. Despite previous concerns over the safety of

EFV based on preclinical animal studies and retrospective case reports in human subjects, the current data do not provide evidence of excess teratogenicity above the expected baseline for infants exposed to EFV in the first selleck products trimester. Sufficient numbers of first trimester exposures of EFV have been monitored to detect at least a twofold increase in risk of overall birth defects within the APR, and no such increases have been detected to date [21]. Data from Côte d’Ivoire found no significant increased risk of unfavourable pregnancy outcome in women with first-trimester exposure to EFV compared with NVP [22]. A systematic review and meta-analysis of observational cohorts carried out in 2010 [23] and further updated in 2011 [24] reported birth

outcomes among women exposed to EFV during the first trimester. No increased risk of overall birth defects among the babies of women exposed to EFV during the first trimester compared with exposure to other ARV drugs was found. The prevalence of overall birth defects with Enzalutamide first-trimester EFV exposure was similar to the ranges reported in the general population. A review pheromone of live births to women with HIV in a large unselected UK population between 1990 and 2007 found no increased risk of abnormalities in infants exposed to EFV in the first trimester, providing further reassurance that ART in utero does not pose a major risk of fetal anomaly [25]. Mathematical modelling using North American cohort data has demonstrated a theoretical loss of life expectancy in women who delay EFV at initiation

of ARV [26]. Based on current evidence, EFV can be initiated in women of childbearing potential, can be continued in women who conceive on the drug and commenced in pregnancy but the data should be discussed in detail with the individual woman when deciding on her preferred treatment regimen. Given that no ARV drug is licensed for use in pregnancy apart from ZDV in the third trimester, a discussion regarding the potential unknown long- and short-term effects on an unborn child should be had with any woman of childbearing potential who commences any ARV drug regimen. Further details can be found in the BHIVA pregnancy guidelines [1]. Significant pharmacokinetic and pharmacodynamic interactions have been reported between ARV drugs and hormonal agents.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>